Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: CIRP promotes the progression of non-small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1

Fig. 1

Elevated Expression of CIRP in NSCLC Samples Correlates with Poor Prognosis. (A) mRNA levels of CIRP were quantified in NSCLC samples and their corresponding noncancerous lung tissues as well as normal lung tissues by qRT-PCR (n = 8). CIRP expression was normalized to GAPDH expression and each noncancerous lung tissue was used as a control. Data are shown as the mean ± SD (**, P < 0.01). (B) The protein level of CIRP was determined by immunoblotting. GAPDH expression served as an endogenous reference. (C) Immunohistochemical analysis of CIRP expression was performed in NSCLC samples and their corresponding noncancerous lung tissues. Representative microphotographs of CIRP expression are displayed. (D) Representative microphotographs showed strong, moderate and weak staining of CIRP in NSCLC tissues and their corresponding noncancerous lung tissues by IHC in a tissue array (magnification × 40). (E) The percentages of strong, moderate and weak CIRP expression in NSCLC samples and corresponding noncancerous lung tissues are shown in pie charts. (F) Kaplan-Meier analysis of the overall survival of NSCLC patients according to the expression level of CIRP protein in NSCLC tissues (CIRP high -expression, n = 48 and CIRP low -expression, n = 38)

Back to article page